Alerta

ナノ構造体及びその用途

Resumen de: CN118922213A

The present application relates to a plurality of spherical nanostructures having a dispersion of between 1 and 1.8 and a volume average hydrodynamic diameter of from 13 nm to 90 nm; wherein each nanostructure comprises a polymeric framework of monomer residues, wherein the average number of bonds from each monomer residue is in the range from 3.0 to but not including 6.0; wherein at least 90% of the monomer residues comprise two gem-chelating groups, each chelating group being independently PO (OR1) (OR2); wherein R1 and R2 are independently selected from the group consisting of a negative charge and H; and '-' represents an internal bond in a monomer residue. The invention also relates to a method for producing the nanostructure, a use of the nanostructure and a pharmaceutical composition comprising the nanostructure.

用于PCSK9表达的表观遗传调节的组合物和方法

Resumen de: AU2023265968A1

This application relates to compositions and methods comprising epigenetic editors for epigenetic modification of

一种人源重组单链抗体、纳米颗粒和纳米药物组合物及其应用

Resumen de: CN119823277A

本发明涉及抗体药物技术领域，尤其涉及一种人源重组单链抗体、纳米颗粒和纳米药物组合物及其应用。本发明提供了一种特异性抗PHD2的人源重组单链抗体，所述人源重组单链抗体的氨基酸序列如SEQ ID NO:2所示。本发明得到的人源重组单链抗体较INP更稳定，器官和组织靶向性好。将该人源重组单链抗体与介孔硅纳米颗粒和红细胞膜组合制备成纳米药物组合物，该纳米药物组合物具有更好的治疗疾病的功效。

靶向肿瘤微环境的带负电蜂毒肽纳米胶囊的制备方法

Resumen de: CN119818456A

靶向肿瘤微环境的带负电蜂毒肽纳米胶囊的制备方法，属于靶向肿瘤药物领域。利用蜂毒肽的疏水作用力及氢键作用力，将单体和交联剂富集在蜂毒肽周围，同时加入能够靶向肿瘤细胞表面唾液酸受体的苯硼酸，随后加入引发剂诱导单体和交联剂的聚合，形成交联网络包封蜂毒肽，大幅度提升了药物在体循环后的肿瘤靶向性，降低其对正常组织的毒副作用。大大提升了蜂毒肽在体内的循环时间。

一种负载姜黄素的虫胶脂质体双层混合纳米颗粒、制备方法及其应用

Resumen de: CN119818443A

一种负载姜黄素的虫胶脂质体双层混合纳米颗粒、制备方法及其应用，属于脂质体纳米颗粒制备技术领域。提供了一种负载姜黄素的虫胶脂质体双层混合纳米颗粒，包含负载有姜黄素的虫胶纳米粒子，并在虫胶纳米粒子的表面包被有脂质体双层结构。还提供了上述负载姜黄素的虫胶脂质体双层混合纳米颗粒的制备方法：将姜黄素和虫胶溶于乙醇中，制备有机相共溶液，制备姜黄素@虫胶纳米颗粒。将磷脂和胆固醇溶于乙醇中，制备有机相共融液。制备不同浓度的姜黄素@虫胶浓度的分散液。制备负载姜黄素的虫胶脂质体双层混合纳米颗粒。本发明纳米颗粒大小均一，具有良好的生物相容性和生物降解性，无毒、无刺激，无需加入表面活性剂，进一步降低了毒性。

一种呼吸道合胞病毒mRNA疫苗及其制备方法和应用

Resumen de: CN119818668A

本发明公开了一种呼吸道合胞病毒mRNA疫苗及其制备方法和应用，通过对preF抗原序列进行密码子优化，选择合适的启动子、5’‑UTR、3’‑UTR和3’‑端PolyA组合成完整的编码RSV病毒preF的序列，再经合成、反转录、纯化得到mRNA，并在5条兼顾表达水平和稳定性的核酸序列中筛选获得2条细胞水平表达preF蛋白的稳定性高以及与中和抗体的结合能力强的序列；并改进了脂质纳米颗粒的组分，增强目的抗原在体内的表达，使得制备得到的mRNA疫苗，免疫小鼠后产生强烈且持久的免疫效果且对病毒的保护力更强。

用于脂质纳米颗粒制剂的脂质

Resumen de: AU2023338228A1

Compounds are provided having the following Structure (I): or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R

一种蛋白基生物材料及其制备方法与应用

Resumen de: CN119823289A

本发明实施例公开了一种蛋白基生物材料及其制备方法与应用。所述方法包括：构建含有编码类胶原蛋白基因和刺猬蛋白基因的重组载体，经表达，纯化后，得到重组蛋白；将重组蛋白与胆固醇在TBS缓冲液存在下进行反应，得到所述蛋白基生物材料。本发明提供的具有功能性的胆固醇修饰多肽的混合生物材料，并在纳米尺度上表现出可编程的自组装，在治疗糖尿病等疾病、组织修复、组织工程支架和治疗、药物递送等生物医学原材料，具有较大的市场价值潜力，为未来生物医用材料的发展做出贡献。

一种GSH响应型西达本胺异二聚体纳米前药及其制备方法与应用

Resumen de: CN119823140A

本发明涉及医药技术领域，公开了一种GSH响应型西达本胺异二聚体纳米前药及其制备方法与应用，本法制得的GSH响应型西达本胺异二聚体纳米前药负载率高，能高效递送到肿瘤细胞，具有精准释放的能力，并通过协同化疗提高了乳腺癌的治疗效果，采用本法制得的前药能够将CDA和CPT高效递送至肿瘤细胞，实现药物在肿瘤细胞的高效递送和按需释放，提高化疗药物的抗肿瘤效果，以此为化疗药物递送提供了新方向和新思路。

一种GSH响应的蛋白降解与化疗药物偶联的抗肿瘤纳米制剂及其制备方法和应用

Resumen de: CN119818457A

本发明公开了一种GSH响应的蛋白降解与化疗药物偶联的抗肿瘤纳米制剂及其制备方法和应用，属于药学技术领域。本发明基于靶向EGFR蛋白降解剂基础上通过GSH响应性二硫键与化疗药物DOX进行偶联得到PDC‑S，使PROTAC分子本身能够在水溶中自组装成纳米粒。因此，本发明不仅提高了PROTAC的水溶性而且可以发挥纳米粒所具备的优势，而且为改善PROTAC所面临的问题提供了一种解决方案。

一种低刺激性、宠物用制霉菌素软膏及其制备方法

Resumen de: CN119818432A

本发明属于药物制备技术领域，具体涉及一种低刺激性、宠物用制霉菌素软膏及其制备方法。提供了一种低刺激性、宠物用制霉菌素软膏，按照质量100％计，包括以下原料：硫酸新霉素0.1‑0.5％、缓释型制霉菌素5‑25％、曲安奈德0.05‑0.2％、氯菊酯纳米粒子0.1‑2.5％、其余为石蜡。本发明提供了一种低刺激性、宠物用制霉菌素软膏，通过对其中的原料组分进行改性、优化，得到一种杀菌性好、成分稳定、低刺激性的制霉菌素软膏，有利于治疗宠物的真菌性感染疾病。

高效控释NO的蝴蝶形肽类树状大分子及其合成方法

Resumen de: CN119823214A

本发明属于生物医药技术领域，具体公开了高效控释NO的蝴蝶形肽类树状大分子及其合成方法。本发明还公开了的蝴蝶形肽类树状大分子合成的递送系统。本发明提供的蝴蝶形肽类树状大分子和递送系统有望成为治疗糖尿病足溃疡的药物。

负载重组牛干扰素α/γ壳聚糖纳米颗粒的制备方法及其应用

Resumen de: CN119818449A

本发明提供了一种负载重组牛干扰素α/γ壳聚糖纳米颗粒(CS‑TPP‑rBoIFNα/γNPs)的制备方法，制备方法包括：重组牛干扰素α/γ(rBoIFNα/γ)的表达与纯化、rBoIFNα/γ的复性和CS‑TPP‑rBoIFNα/γNPs的制备。还提供了应用，用于制备防治BVDV引起的犊牛腹泻药物。本发明制备的CS‑TPP‑rBoIFNα/γNPs尺寸较小呈均匀分布，在生物体液中可持续释放96h；且CS‑TPP‑rBoIFNα/γNPs包封效果较好，封装效率和负载效率可达76.3％、67.2％；在小鼠体内应用发现CS‑TPP‑rBoIFNα/γNPs能够显著提高rBoIFNα/γ的抗病毒活性。

一种近红外光致半导体聚合物及其水解产物、侧链修饰聚合物、药物递送系统、光刺激响应纳米递送系统及制备方法和应用

Resumen de: CN119823356A

本发明提供了一种近红外光致半导体聚合物及其水解产物、侧链修饰聚合物、药物递送系统、光刺激响应纳米递送系统及制备方法和应用，涉及生物医药技术领域。本发明提供的近红外光致半导体聚合物及其水解产物、侧链修饰聚合物、药物递送系统（OPTC）和光刺激响应纳米递送系统（OPTC‑RNP）在近红外二区成像时，均具有较低的自发背景荧光、较深的组织穿透性和较高的信噪比，近红外二区成像效果优异，可观察到纳米递送系统在肿瘤部位的积累。而且，递送系统中光敏剂能够在近红外光的照射下产生单线态氧，实现肿瘤光动力治疗的同时，可打断OPTC与RNP间连接的化学键而释放核糖核蛋白复合体（RNP），实现光可控的基因治疗。

ＲＮＡコンストラクトおよびその使用

Resumen de: MX2024011779A

Disclosed herein are RNA polynucleotides comprising a 5' Cap, a 5' UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.

ウイルス模倣性ナノ粒子

Resumen de: US2022409743A1

The present invention relates to a nanoparticle comprising a nanomaterial and at least a first ligand and a second ligand tethered to the nanoparticle. The present invention further relates to a nanoparticle for use as a medicament or diagnostic agent. The present invention also relates to a nanoparticle for use in a method of preventing or treating a disease selected from diabetic nephropathy, glomerulonephritis, glomerular VEGF A dysregulation, endothelial VEGF A dysregulation, diabetic retinopathy, rheumatoid arthritis, age-related macular degeneration, and cancer such as breast cancer. Furthermore, the present invention relates to a method of preparing a nanoparticle.

新規のイオン化脂質および脂質ナノ粒子ならびにそれらを使用する方法

Resumen de: MX2024011629A

The disclosure relates to novel ionizable lipids and lipid compositions and pharmaceutical compositions comprising these ionizable lipids that can be used in the delivery of therapeutic agent.

呼吸器合成ウイルス抗原組成物および方法

Resumen de: MX2024011975A

Described herein is a composition including particles, the particles including a multilayer film, the multilayer film including two or more layers of polyelectrolytes, wherein adjacent layers include oppositely charged polyelectrolytes, wherein one of the polyelectrolytes is a designed polypeptide having the structure: (Pam3Cys or Pam2Cys)- (surface adsorption region one)- (RSV-G peptide epitope)-L1- (RSV-M2 peptide epitope)-L2- (surface adsorption region two).

疎水性薬剤のナノ懸濁液および非晶質固体分散物ならびにそれらの使用方法

Resumen de: US2025000812A1

Described herein, in certain aspects, are nano-suspensions comprising a plurality of nanoparticles comprising a hydrophobic agent suspended in an aqueous carrier having a desired viscosity. In other aspects, the described herein are methods of use thereof, including methods of making a dosage form, components of the nano-suspensions, dispensing cartridges and composition therein, dosage forms, devices for dispensing a nano-suspension, and system and applications of the embodiments described herein.

異種プライムブーストワクチン組成物及び使用の方法

Resumen de: CN119072330A

Described herein are methods of inducing an immune response in a subject comprising administering a prime-boost vaccine wherein the prime vaccine comprises DNA (e.g., ceDNA) encoding a first peptide, and the boost vaccine comprises (i) a ribonucleic acid (RNA) or (ii) a second peptide. Also provided are vaccine regimens comprising: a prime vaccine comprising DNA wherein the DNA encodes a first peptide; and a booster vaccine comprising (i) a ribonucleic acid (RNA) or (ii) a second peptide, where the RNA encodes the second peptide.

送達ベシクルを製造するための方法

Resumen de: CN118871133A

The present invention relates to the development of vesicles useful in the production of vaccines or as compound delivery vectors. More specifically, the present invention relates to a method for preparing vesicles comprising the steps of: providing recombinant trypanosoma buchneri cells expressing sortable VSG; treating the cells in a hypotonic solution in the presence of at least one protease inhibitor until the cells are lysed; separating a cell membrane from the solution; suspending the separated cell membrane obtained previously in an isotonic solution; treating the suspension cell membrane obtained in the previous step by ultrasonic treatment to obtain a vesicle suspension; removing aggregated membrane-like fragments from the previously obtained vesicle suspension; separating the suspension of vesicles into a population of vesicles; and providing vesicles from the population of vesicles characterized by (i) having a single dominant protein shown after Coomassie staining SDS PAGE with an apparent molecular weight of 55 to 60 kDa, (ii) having a spherical appearance under electron microscopy, and (iii) exhibiting a uniform surface structure under electron microscopy. Furthermore, the present invention relates to vesicles comprising sortable VSGs characterized by the above parameters, as well as such vesicles for use in the treatment and/or prevention of a disease or medical condition, or as compound delivery vesicles, preferably drug delivery vehicles, more preferably nucl

ＧＮＡＱ及びＧＮＡ１１駆動疾患の治療方法

Resumen de: AU2023232895A1

The present invention relates to novel compositions and methods of treating clinical conditions arising from GNAQ and GNA11 somatic mutations including cancer, Sturge-Weber syndrome (SWS), Phakomatosis Pigmentovascularis (PPV), Extensive Dermal Melanocytosis (EDM) and congenital hemangiomas (including rapidly involuting congenital hemangioma (RICH), partially involuting congenital hemangioma (PICH) and non-involuting congenital hemangioma (NICH)).

緑内障の処置方法

Resumen de: CN119053704A

The present disclosure relates generally to methods of treating, preventing, and/or delaying the progression of glaucoma in a subject comprising administering an antisense oligonucleotide that modulates mRNA productive transcript, stability, and/or translation of an OPA1 gene transcript or a portion thereof.

がんの処置において有用なＴｏｌｌ様受容体（「ＴＬＲ」）アゴニストプロドラッグを含有する製剤化および／または共製剤化脂質ナノキャリア組成物ならびにその方法

Resumen de: CN119013045A

Disclosed herein are formulated and/or co-formulated nanocarriers comprising a TLR prodrug and/or a TLR lipid moiety, and methods of making the nanocarriers. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and a linking unit that inhibits Toll-like receptors (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs may be formulated and/or co-formulated into nanocarriers (e.g., LNPs or SLNPs) to provide methods of treating cancer, immune disorders, and other diseases by utilizing targeted drug delivery vehicles.

非対称ピペラジン系カチオン性脂質

Nº publicación: JP2025509507A 11/04/2025

Solicitante:

トランスレイトバイオ，インコーポレイテッド

Resumen de: CN118922409A

The present invention provides, in part, asymmetric piperazine-based lipid compounds of Formula (I ') and their sub-formulae or pharmaceutically acceptable salts thereof. The compounds provided herein may be useful for delivery and expression of mRNA and encoded proteins, for example as components of liposomal delivery vehicles, and thus may be useful in the treatment of various diseases, disorders and conditions, such as those associated with the lack of one or more proteins.